Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani
暂无分享,去创建一个
T. Phan | J. No | Yeon Ju Kim | Ahmed H. E. Hassan | Waleed A Bayoumi | S. M. El-Sayed | Kazem Mahmoud | Soo-Bin Cho | Y. S. Lee | Tae-Hwan Oh | C. Lee | G. Ham
[1] Jong-Hyun Park,et al. Synthesis and Biological Evaluation of O6-Aminoalkyl-Hispidol Analogs as Multifunctional Monoamine Oxidase-B Inhibitors towards Management of Neurodegenerative Diseases , 2023, Antioxidants.
[2] E. Ricci-Júnior,et al. Nanoparticles for the treatment of visceral leishmaniasis: review , 2023, Journal of Nanoparticle Research.
[3] S. Robledo,et al. A Biologically Active Chromone from Bomarea setacea ( alstroemeriaceae ): Leishmanicidal, Antioxidant and Multilevel Computational Studies , 2022, ChemistrySelect.
[4] Kyung-Sook Chung,et al. 3',4'-Dihydroxyflavone mitigates inflammatory responses by inhibiting LPS and TLR4/MD2 interaction. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[5] D. Zama,et al. Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics , 2022, Microorganisms.
[6] F. Tuon,et al. Liposomal drug delivery systems for the treatment of leishmaniasis , 2022, Parasitology Research.
[7] T. Phan,et al. Design, Rational Repurposing, Synthesis, In Vitro Evaluation, Homology Modeling and In Silico Study of Sulfuretin Analogs as Potential Antileishmanial Hit Compounds , 2022, Pharmaceuticals.
[8] Prof Vikas Kumar,et al. - Amphotericin B: A drug of choice for Visceral Leishmaniasis. , 2022, Acta tropica.
[9] E. Akl,et al. Stakeholders’ views and perspectives on treatments of visceral leishmaniasis and their outcomes in HIV-coinfected patients in East Africa and South-East Asia: A mixed methods study , 2022, PLoS neglected tropical diseases.
[10] F. Dumetz,et al. Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis , 2022, Frontiers in Tropical Diseases.
[11] Kyung-Sook Chung,et al. Mosloflavone-Resveratrol Hybrid TMS-HDMF-5z Exhibits Potent In Vitro and In Vivo Anti-Inflammatory Effects Through NF-κB, AP-1, and JAK/STAT Inactivation , 2022, Frontiers in Pharmacology.
[12] Ki Duk Park,et al. Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases , 2022, Journal of enzyme inhibition and medicinal chemistry.
[13] N. Karunaweera,et al. Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review , 2022, Infectious Diseases and Therapy.
[14] Kyung-Sook Chung,et al. AKF-D52, a Synthetic Phenoxypyrimidine-Urea Derivative, Triggers Extrinsic/Intrinsic Apoptosis and Cytoprotective Autophagy in Human Non-Small Cell Lung Cancer Cells , 2021, Cancers.
[15] K. Yadav,et al. Road map to the treatment of neglected tropical diseases: Nanocarriers interventions. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[16] P. Rai,et al. Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches , 2021, Journal of biomolecular structure & dynamics.
[17] Hongqiao Zhang,et al. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy , 2021, Nature Reviews Drug Discovery.
[18] Mohammed A Alaidarous,et al. Repurposing of FDA‐approved drugs as inhibitors of sterol C‐24 methyltransferase of Leishmania donovani to fight against leishmaniasis , 2021, Drug development research.
[19] Marco Biasini,et al. ProMod3—A versatile homology modelling toolbox , 2021, PLoS Comput. Biol..
[20] Yong Sup Lee,et al. Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani , 2021, Journal of enzyme inhibition and medicinal chemistry.
[21] P. Fernandes,et al. Evolution of chromone-like compounds as potential antileishmanial agents, through the 21st century , 2020, Expert opinion on drug discovery.
[22] Jaydeep Roy,et al. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II) , 2020, Journal of biomolecular structure & dynamics.
[23] Kyung-Sook Chung,et al. Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. , 2020, Bioorganic chemistry.
[24] R. Bureau,et al. Drug repositioning: a brief overview , 2020, The Journal of pharmacy and pharmacology.
[25] David Shum,et al. In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei , 2020, Molecules.
[26] Ki Duk Park,et al. Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds , 2019, Journal of enzyme inhibition and medicinal chemistry.
[27] S. Braga. Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. , 2019, European journal of medicinal chemistry.
[28] Kyung-Sook Chung,et al. The Anti-Proliferative Activity of the Hybrid TMS-TMF-4f Compound Against Human Cervical Cancer Involves Apoptosis Mediated by STAT3 Inactivation , 2019, Cancers.
[29] Kyung-Tae Lee,et al. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. , 2019, European journal of medicinal chemistry.
[30] C. Nakamura,et al. trans‐Chalcone modulates Leishmania amazonensis infection in vitro by Nrf2 overexpression affecting iron availability , 2019, European journal of pharmacology.
[31] R. Casagrande,et al. Quercetin promotes antipromastigote effect by increasing the ROS production and anti-amastigote by upregulating Nrf2/HO-1 expression, affecting iron availability. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[32] Jongki Hong,et al. Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. , 2019, Bioorganic chemistry.
[33] D. Murrell,et al. Cutaneous leishmaniasis: A neglected disfiguring disease for women , 2019, International journal of women's dermatology.
[34] Ji-Sun Shin,et al. Natural products hybrids: 3,5,4'-Trimethoxystilbene-5,6,7-trimethoxyflavone chimeric analogs as potential cytotoxic agents against diverse human cancer cells. , 2019, European journal of medicinal chemistry.
[35] Torsten Schwede,et al. SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..
[36] S. Nixdorf,et al. Caryocar coriaceum extracts exert leishmanicidal effect acting in promastigote forms by apoptosis-like mechanism and intracellular amastigotes by Nrf2/HO-1/ferritin dependent response and iron depletion: Leishmanicidal effect of Caryocar coriaceum leaf exracts. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[37] L. B. de Arruda,et al. The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity. , 2017, Parasitology international.
[38] Torsten Schwede,et al. The SWISS-MODEL Repository—new features and functionality , 2016, Nucleic Acids Res..
[39] Ariel Chernomoretz,et al. A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases , 2016, PLoS neglected tropical diseases.
[40] M. Dacher,et al. Implication of different domains of the Leishmania major metacaspase in cell death and autophagy , 2015, Cell Death and Disease.
[41] S. Robledo,et al. Synthesis, Leishmanicidal and Cytotoxic Activity of Triclosan-Chalcone, Triclosan-Chromone and Triclosan-Coumarin Hybrids , 2014, Molecules.
[42] Jim Euchner. Design , 2014, Catalysis from A to Z.
[43] T. Souto-Padrón,et al. The Calpain Inhibitor MDL28170 Induces the Expression of Apoptotic Markers in Leishmania amazonensis Promastigotes , 2014, PloS one.
[44] Branquinha Mh,et al. Calpains: Potential Targets for Alternative Chemotherapeutic Intervention Against Human Pathogenic Trypanosomatids , 2013, Current medicinal chemistry.
[45] S. Sundar,et al. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani , 2013, Parasitology Research.
[46] J. Cano,et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.
[47] S. Maiti,et al. Protective Therapy with Novel Chromone Derivative against Leishmania donovani Infection Induces Th1 Response in vivo , 2011, Chemotherapy.
[48] Seo Yun Jung,et al. Synthesis of chromone carboxamide derivatives with antioxidative and calpain inhibitory properties. , 2011, European journal of medicinal chemistry.
[49] G. H. Coombs,et al. α‐Ketoheterocycles as Inhibitors of Leishmania mexicana Cysteine Protease CPB , 2010, ChemMedChem.
[50] Yong Sup Lee,et al. Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. , 2009, European journal of medicinal chemistry.
[51] J. L. Martins,et al. Antileishmanial activity of MDL 28170, a potent calpain inhibitor , 2006, International Journal of Antimicrobial Agents.
[52] L. Leon,et al. Leishmaniasis treatment: update of possibilities for drug repurposing. , 2018, Frontiers in bioscience.
[53] Yong Sup Lee,et al. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents , 2018, Archives of pharmacal research.
[54] S. Robledo,et al. Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids , 2017 .